Log in to save activitiesYour saved activities will show here so that you can easily access them whenever you're ready. Log in hereCME & EducationLog in to keep track of your credits.
Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Morbidity & Mortality Weekly Report, December 2021
New and Emerging Agents for Dyslipidemia CME / ABIM MOC / CEDr Ballantyne reviews mechanisms or action and current clinical trial data of emerging agents for the treatment of dyslipidemia.
Gout is defined as an arthritis associated with the presence of MSU crystals in synovial fluid or tissue. Gout is often classified as primary or secondary and both forms are associated with hyperuricemia. Gout associated with an inborn error in metabolism or decreased renal excretion without other renal disease is referred to as primary gout, whereas gout associated with an acquired disease or the use of a drug is called secondary gout. In both primary and secondary gout, chronic hyperuricemia may be the result of overproduction of uric acid caused by increased purine intake, synthesis, or breakdown, or it may be the result of decreased renal excretion of urate.
